Compass Therapeutics, Inc. (CMPX)
After hours:
| Previous close | 1.4100 |
| Open | 1.4300 |
| Bid | 1.3500 x 400 |
| Ask | 1.3800 x 500 |
| Day's range | 1.3300 - 1.4600 |
| 52-week range | 1.1500 - 3.4500 |
| Volume | |
| Avg. volume | 303,123 |
| Market cap | 187.121M |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3500 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.83 |
GlobeNewswireCompass Therapeutics to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place in New York City, NY June 5 – 6, 2024. Fireside Chat detailsDate: Wednesday, June 5, 2024 Time: 1:00 – 1:25 PM ETWebcast Link: https://wsw.com
- GlobeNewswire
Compass Therapeutics Announces CEO Transition
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered B
- GlobeNewswire
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors.Five clinical responses were observed, all in patients who previously received checkpoint inhibitors. A durable partial response (PR) in a patient with small-cell lung cancer (SCLC) converted to a complete resp
